Full immunization definition

Full immunization means the same as defined in RCW 28A.210.070(2).
Sample 1Sample 2Sample 3
Full immunization means immunization against certain
Sample 1Sample 2Sample 3
Full immunization means immunization against certain vaccine-preventable diseases in accordance with schedules and with immunizing agents approved by the state board of health.
Sample 1Sample 2Sample 3

Examples of Full immunization in a sentence

  • Full immunization requires 3 doses of vaccine over a six-month period, although some persons may not develop immunity even after 3 doses.

  • Full immunization requires 5 shots, ideally before the child turns 2.

  • Full immunization of a child includes eight recommended vaccines – BCG, DPT1, DPT2, DPT3, Polio1, Polio 2, Polio 3 and measles.

  • Full immunization against Hepatitis B consists of three timed doses of vaccine over a minimum 4 to 6 months period.

  • Full immunization coverage in Mizoram was 50.7 percent, compared to 62.0 percent nationally.

  • Full immunization requires three doses of vaccine over a six-month period although some persons may not develop immunity even after three doses.

  • Full immunization requires three doses of the vaccine over a six month period.

  • The Annual Bonus for achievement of all Bonus Objectives at target (the “Target Bonus Amount”) will be seventy-five percent (75%) of the Base Salary paid in such fiscal year (or pro rata as to any portion of the fiscal year), but the actual amount of the Annual Bonus may exceed 75% of Base Salary based on overachievement of the Bonus Objectives as adopted by the Compensation Committee.

  • Full immunization of a vaccine refers to all required doses of a specific vaccine (e.g., three doses of HPV).

  • If there are more than one qualified proponent, the Government will select the successful proponent by drawing lots in the presence of a witness.


More Definitions of Full immunization

Full immunization or "fully immunized" means an immunization status where a child has provided proof of acquired immunity or has been vaccinated with immunizing agents against each of the vaccine-preventable diseases listed in WAC 246-105-030 according to the national immuniza- tion guidelines described in WAC 246-105-040.
Sample 1Sample 2

Related to Full immunization

  • Study means the investigation to be conducted in accordance with the Protocol.

  • HIV means human immunodeficiency virus.

  • Pharmacist preceptor or “preceptor” means a pharmacist licensed to practice pharmacy whose license is current and in good standing. Preceptors shall meet the conditions and requirements of rule 657—4.9(155A). No pharmacist shall serve as a preceptor while the pharmacist’s license to practice pharmacy is the subject of disciplinary sanction by a pharmacist licensing authority.

  • Collaborating physician means the physician who,

  • Cardiopulmonary resuscitation or "CPR" means artificial ventilation or external chest compression applied to a person who is unresponsive and not breathing.

  • Phase I Trial means a clinical trial of a Licensed Product in human patients conducted primarily for the purpose of determining the safety, tolerability and preliminary activity of the Licensed Product, including, without limitation, for determining the maximum tolerated dose, or optimal dose. For purposes of this Agreement, a Phase I trial shall specifically exclude a study in healthy volunteers.

  • Clinical laboratory means a facility for the microbiological, serological, chemical, hematological, radiobioassay, cytological, immunohematological, pathological, or other examination of materials derived from the human body for the purpose of providing information for the diagnosis, prevention, or treatment of a disease or assessment of a medical condition.

  • Phase III Trial means a human Clinical Trial of the Licensed Product, which trial is designed (a) to establish that the Licensed Product is safe and efficacious for its intended use; (b) to define warnings, precautions and adverse reactions that are associated with the Licensed Product in the dosage range to be prescribed; and (c) consistent with 21 CFR § 312.21(c).

  • Speech pathologist means a person who engages in the application of principles, methods, and procedures for the measurement, testing, evaluation, prediction, consultation, counseling, instruction, habilitation, rehabilitation, or remediation related to the development and disorders of speech, fluency, voice, or language for the purpose of nonmedically evaluating, preventing, ameliorating, modifying, or remediating such disorders and conditions in individuals or groups of individuals.

  • Investigational Medicinal Product means the study drug or control material as defined in the Protocol.

  • Therapeutic diet means meals served that are soft, low-fat, low-sodium or controlled calorie.

  • Therapeutic school means a residential group living facility:

  • Collaborative drug therapy management means participation by an authorized pharmacist and a physician in the management of drug therapy pursuant to a written community practice protocol or a written hospital practice protocol.

  • Medication means any drug, chemical, compound, suspension, or preparation in suitable form for use as a curative or remedial substance taken either internally or externally by any person.

  • Phase II Trial means a clinical trial of a Licensed Product on patients, including possibly pharmacokinetic and dose ranging studies, the principal purposes of which are to make a preliminary determination that such Licensed Product is safe for its intended use and to obtain sufficient information about such Licensed Product’s efficacy to permit the design of further clinical trials, and generally consistent with 21 CFR §312.21(b), or its successor regulation, or the equivalent in any foreign country.

  • Pivotal Clinical Trial means a clinical study of an investigational product in patients with the primary objective of confirming with statistical significance the efficacy and safety with the aim to obtain regulatory approval in any country as described in 21 C.F.R. 312.21(c), or a comparable clinical study prescribed by the relevant regulatory authority in a country other than the United States.